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Abstract—Physiological hypertrophy represents the adaptive changes of the heart required for supporting the increased
hemodynamic load in regularly trained healthy subjects. Mechanisms responsible for the athlete’s hypertrophy still
remain unknown. In 15 trained competitive soccer players and in 15 healthy men not engaged in sporting activities
(sedentary control subjects) of equivalent age, we investigated the relationship among cardiac growth factor formation,
cardiac sympathetic activity, and left ventricular morphology and function. Cardiac formation of insulin-like growth
factor (IGF)-I, endothelin (ET)-1, big ET-1, and angiotensin (Ang) II was investigated at rest by measuring
artery–coronary sinus concentration gradients. Cardiac sympathetic activity was studied by [3H]norepinephrine (NE)
kinetics. Cardiac IGF-I, but not ET-1, big ET-1, and Ang II, formation was higher in athletes than in control subjects
(P0.01). NE levels in arterial and peripheral venous blood did not differ between groups. In contrast, coronary sinus
NE concentration was higher in athletes than in control subjects (P0.01). Cardiac, but not total systemic, NE spillover
was also increased in athletes (P0.01), whereas cardiac [3H]NE reuptake and clearance were not different.
Echocardiographic modifications indicated a volume overload–induced hypertrophy associated with increased myocar-
dial contractility. Multivariate stepwise analysis selected left ventricular mass index as the most predictive independent
variable for cardiac IGF-I formation and velocity of circumferential fiber shortening for cardiac NE spillover. In
conclusion, increased cardiac IGF-I formation and enhanced sympathetic activity selectively confined to the heart
appear to be responsible for the physiological hypertrophy in athletes performing predominantly isotonic exercise. (Circ
Res. 2001;89:977-982.)
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The heart sustains an increased hemodynamic load byadjusting its mass independently of whether the en-
hanced workload is due to physiological activity or to
pathological alterations in the cardiovascular system. There is
much evidence that the development of myocardial hypertro-
phy results from the interaction of mechanical forces (the
increased workload) and cardiac growth factors. The hemo-
dynamic overload leads to myocardial cellular stretch and
strain that in turn induce gene expression of cardiac growth
factors.1,2 In regularly trained healthy subjects, both isotonic
and isometric exercise cause cardiac changes resulting in
modifications of the ventricular chambers and in a notable
enhancement of heart performance. These modifications,
called physiological hypertrophy or athlete’s hypertrophy, are
required for sustaining the tremendous increase in cardiac
output during exercise. Cardiac growth factors involved in the
development of physiological hypertrophy in humans are still
unknown, and their knowledge might also be relevant for
better understanding the mechanisms involved in the cardiac
adaptive response to the pathological increase in hemody-
namic workload. Cardiac formation of several growth factors,
including insulin-like growth factor-I (IGF-I), endothelin
(ET)-1, and angiotensin (Ang) II, has been found to be
increased in human hypertrophy caused by aortic valve
disease and heart failure.3,4
Another major component of cardiac performance during
exercise is the enhancement of sympathetic activity, which
causes an increase in heart rate and contractility and mediates
the cardiovascular and metabolic responses to exercise.5
Sympathetic cardiac activation in relation to physical exercise
has been studied in habitually sedentary subjects during
short-term performance under standardized laboratory proce-
dures,6–9 but information is lacking on sympathetic cardiac
activity during long-lasting sport activity under field condi-
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tions. Therefore, we planned this study to answer the follow-
ing questions: (1) whether cardiac growth factors, specifically
Ang II and IGF-I, are involved in the athlete’s physiological
hypertrophy, and (2) whether and how the cardiac sympa-
thetic system participates in the development and the main-
tenance of physiological hypertrophy.
Materials and Methods
We investigated 15 professional male soccer players aged 264
years who were in full sporting activity at the time of the study. The
athletes trained 2 hours at least 5 times a week and participated in
regular competitions against other professional athletes. The control
group was made up of 15 healthy men, aged 277 years, none of
whom was engaged in sporting activities (sedentary control subjects)
(Table 1).
All subjects were nonsmokers, and none had taken any medica-
tions for at least 3 weeks before the study. Both athletes and control
subjects were referred to the electrophysiological laboratory of our
Institute for arrhythmias (symptomatic sinus bradycardia, n3; sinus
node dysfunction, n3; narrow QRS complex tachycardia, n11;
ventricular preexcitation, n9; and type I second-degree atrioven-
tricular block, n4), documented on resting ECG records or ECG
Holter monitoring. The results of physical examination, other routine
noninvasive diagnostic procedures, and electrophysiological study
did not show the presence of any heart disease. The protocol of this
study complies with the principles of the Helsinki declaration. All
subjects gave their informed written consent to participate and to
have their blood samples used for the study.
Echocardiographic measurements were performed prospectively,
as previously described.3 Cardiac formation of IGF-I, ET-1, big
ET-1, and Ang II was expressed as the artery–coronary sinus
concentration gradient indexed by coronary blood flow (CBF) and
cardiac mass.3 IGF-I, ET-1, and big ET-1 plasma concentrations
were measured by RIA using specific rabbit polyclonal antibodies
after chromatographic extraction, as reported earlier.3 Ang II plasma
concentrations were measured by RIA after HPLC separation as
previously described.3
The study of [3H]norepinephrine (NE) kinetics was performed
according to the method previously reported.10 Briefly, [3H]NE (1.2
Ci L-[7-3H]NE per minute, specific activity 11 to 16 Ci/mmol, New
England Nuclear) was infused for 30 minutes into a peripheral vein
to achieve a steady-state plasma concentration. Total systemic and
cardiac NE spillover into the plasma and total systemic and cardiac
NE clearance were calculated from the following equations:
(1) Total systemic NE spillover

3HNE infusion rate dpm/min
specific radioactivity of plasma dpm/pg
(2) Total systemic NE clearance

3HNE infusion rate dpm/min
plasma 3HNE concentration dpm/mL
(3) Cardiac NE spillover
CBFNE coronary sinus	NE artery

NE arteryNE extraction]
(4) Cardiac NE clearanceNE extractionCBF
Plasma NE and epinephrine levels were assayed by HPLC with
electrochemical detection, and the concentration of [3H]NE was
determined in fractions of the eluent by liquid scintillation counting
after extraction with allumina.10
Unless otherwise specified, data are meanSD. ANOVA was
used to compare athletes and control subjects. For multivariate
reevaluation of univariate correlations, the following were entered in
a stepwise multiple regression analysis as independent variables,
considering cardiac IGF-I formation and cardiac NE spillover as
dependent variables: septal and posterior wall thicknesses, left
ventricular end-diastolic diameter index (LVEDDI), relative wall
thickness, left ventricular mass index (LVMI), left ventricular
ejection fraction, mean midwall velocity of circumferential fiber
shortening (Vcf), end-systolic stress (ESS), and Vcf/ESS ratio.
An expanded Materials and Methods section can be found in the
online data supplement available at http://www.circresaha.org.
Results
Echocardiographic Characteristics
The echocardiographic characteristics of subjects investi-
gated are reported in Table 1. LVMI and LVEDDI, but not
septal and posterior wall thicknesses, were on average higher
in the athletes than in sedentary control subjects (P0.05)
(Table 1). Relative wall thickness was similar in the 2 groups.
Vcf was significantly increased in the athletes compared with
sedentary control subjects (P0.001), whereas left ventricu-
lar ejection fraction and the early-to-atrial peak velocity
(E/A) ratio did not differ between groups (Table 1).
Cardiac Growth Factor Formation
In sedentary control subjects the artery–coronary sinus con-
centration gradient of IGF-I was slightly positive (Figure 1),
indicating a low IGF-I cardiac formation. Conversely, in the
athlete group IGF-I concentration in coronary sinus blood
was significantly higher than in arterial blood, resulting in an
increased positivity of the transcardiac gradient indicative of
enhanced cardiac formation of IGF-I in this group (Figure 1).
The artery–coronary sinus concentration gradients for
ET-1, big ET-1, and Ang II were around 0 in both sedentary
control and athlete groups (Figure 1).
Total Systemic and Cardiac [3H]NE Kinetics
NE concentration in arterial and peripheral venous blood did
not differ between athletes and sedentary control subjects. In
contrast, NE levels in coronary sinus blood were significantly
TABLE 1. Characteristics of Subjects Investigated
Control Subjects (n15) Athletes (n15)
Age, years 277 264
Heart rate, bpm 726 674*
Body surface area, m2 1.870.17 1.860.09
Septal thickness, mm 9.20.9 9.70.8
Posterior wall thickness, mm 9.40.7 9.70.8
RWT, % 37.63.5 37.44.1
LVEDDI, mm/m2 26.61.9 28.61.2*
LVMI, g/m2 10913 13115*
ESS, kdyne/cm2 698 7112
Vcf 1.170.17 1.450.13*
LVEF 655 657
E/A ratio 1.590.31 1.770.55
RWT indicates relative wall thickness; LVEDDI, left ventricular end-diastolic
diameter index; LVMI, left ventricular mass index; ESS, end-systolic stress; Vcf,
mean midwall velocity of circumferential fiber shortening; and LVEF, left
ventricular ejection fraction.
*P0.05 vs control subjects.
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higher in athletes than in control subjects (Table 2), resulting
in both a higher artery–coronary sinus NE concentration
gradient (Table 2) and cardiac NE spillover (Figure 2 and
Table 2). Cardiac [3H]NE fractional extraction and cardiac
NE clearance were not significantly different between groups
(Table 2).
Finally, the total systemic NE spillover and the total
systemic NE clearance did not differ between athletes and
sedentary control subjects (Figure 2, Table 2).
Epinephrine concentrations in the peripheral venous, arte-
rial, and coronary sinus blood were not significantly different
between groups.
Relationship of Cardiac Growth Factors and
of Cardiac NE Spillover to
Echocardiographic Parameters
Cardiac formation of IGF-I was positively related to LVMI
(r0.77, P0.001) and LVEDDI (r0.72, P0.001). In the
multivariate stepwise analysis, the most predictive indepen-
dent variable for cardiac IGF-I formation was LVMI
(r0.77, P0.001) (Figure 3 and Table 3). Univariate
regression analysis showed that cardiac NE spillover was
positively correlated with the indexes of ventricular contrac-
tility (Vcf, r0.81, P0.001; Vcf/ESS, r0.66, P0.001).
The multivariate stepwise analysis revealed that Vcf was the
most predictive independent variable for cardiac NE spillover
(r0.81, P0.001) (Figure 3, Table 3).
Figure 1. Artery–coronary sinus gradi-
ents indexed by coronary blood flow
and cardiac mass (cardiac formation)
of IGF-I (A), Ang II (B), big ET-1 (C),
and ET-1 (D) in control () and athlete
() groups. *P0.05 vs control group.





Arterial blood, pg/mL 24572 22385
Coronary sinus blood, pg/mL 19564 32174
A-CS gradient, pg/mL 	5626 4625*
Cardiac NE spillover, ng/min 51 81*
Cardiac [3H]NE fractional extraction, % 628 627
Cardiac NE clearance, mL/min 526 537
Total systemic NE spillover, ng/min 63668 632101
Total systemic NE clearance, mL/min 172785 172099
A-CS indicates aorta-coronary sinus.
*P0.01 vs control subjects.
Figure 2. Cardiac NE spillover (A),
total systemic NE spillover (B), car-
diac [3H]NE fractional extraction (C),
and total systemic NE clearance (D)
in athletes. Numbers under columns
are meanSD. *P0.05 vs control
group.
Figure 3. Correlation between IGF-I cardiac formation and LVMI
(A) and between cardiac NE spillover and velocity of Vcf (B) in
athletes.
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Discussion
The results of this study show for the first time that increased
cardiac IGF-I formation and enhanced sympathetic activity
selectively confined to the heart are associated with, and
likely responsible for, the physiological hypertrophy of pro-
fessional athletes performing mainly isotonic exercise, such
as soccer players.
Echocardiographic Characteristics
The development of athlete’s hypertrophy is associated with
important and specific adaptations of the cardiovascular
system. Cardiac adaptations, in particular, are characterized
by an increase in left ventricular mass and ventricular wall
thickness, with or without cavity dimension increase.11,12
Different types of exercise and athlete training influence the
characteristics of cardiac hypertrophy. Generally, but not
necessarily,13 eccentric hypertrophy occurs predominantly in
endurance athletes doing isotonic exercise, as a result of a
volume-loading effect,14 whereas concentric hypertrophy is
seen in strength athletes performing isometric exercise result-
ing in a pressure-loading effect.11,13,15 The echocardiographic
changes found in our athlete group were characterized by
increases in LVMI, LVEDDI, and, to a lesser extent, left
ventricular wall thickness. These echocardiographic modifi-
cations are characteristic of cardiac hypertrophy mainly as a
result of volume overload, as occurs in soccer players.16,17
Although the LVEDDI of athletes was higher than that of
sedentary subjects, it remained within generally accepted
normal limits.11,12,18,19 Moreover, the increase in LVEDDI
was associated with enhanced myocardial contractility indi-
cating that cavity dilatation in these subjects is an expression
of cardiac physiological adaptation to a well-accepted volume
overload with consequent improvement of myocardial re-
sponse to the Frank-Starling relationship and consequent
increase in stroke volume.
Cardiac Growth Factor Formation and Its
Relationship to Echocardiographic Changes
In the present study, cardiac formation of growth factors was
estimated only by measuring the artery–coronary sinus con-
centration gradient of the individual growth factors because,
for ethical reasons, we did not perform myocardial biopsies to
quantify mRNA levels of the relative peptides. There is no
evidence that IGF-I and ET-1 undergo important metabolic
changes during the transcardiac passage, and in previous
studies significant increases or decreases in the aorta–coro-
nary sinus concentration gradients of IGF-I or ET-1 were
associated with concomitant changes of their mRNA levels,3,4
thus indicating that the measurement of the transcardiac
gradients of these growth factors may serve as a reliable index
of their cardiac production at rest. In contrast to IGF-I and
ET-1, both angiotensins undergo important metabolic
changes during transcardiac passage. In normal subjects,
30% of the Ang I passing through the heart is extracted,
partially converted to Ang II, and partially degraded by
angiotensinases into smaller inactive peptides.20 Ang II is also
partially extracted (20%) during the transcardiac passage.20
The final result of these metabolic changes of both angioten-
sins is that in normal subjects the aorta–coronary sinus
gradient is0, notwithstanding the cardiac generation of Ang
I and Ang II.20 When cardiac Ang formation is increased, the
aorta–coronary sinus concentration gradient of both angio-
tensins is significantly increased3,4 and parallels elevated
myocardial levels of angiotensin-converting enzyme and
angiotensinogen mRNAs.3,4,20 Thus, the lack of difference
between concentration gradients of ET-1, big ET-1, and both
angiotensins in the athlete group and those of the sedentary
control group suggests that cardiac formation of these growth
factors is not increased in well-trained soccer players.
Conversely, IGF-I appears to be the only cardiac growth
factor associated with the hypertrophy of trained soccer players,
because the IGF-I artery–coronary sinus concentration gradient
was significantly higher in the athlete group than in the sedentary
control subjects, thus indicating increased cardiac IGF-I forma-
tion. The isolated increase in IGF-I formation and the absence of
enhanced cardiac generation of ET-1 in this group are consistent
with the volume overload–induced eccentric hypertrophy, result-
ing from an essentially dynamic exercise, such as that performed
by soccer players. Thus, it is not surprising that the pattern of
cardiac growth factor formation in physiological hypertrophy is
similar to that found in volume-overload hypertrophy caused by
the experimental creation of an aorta-cava fistula, where IGF-I
appears to be the only cardiac growth factor produced,21 whereas
hypertrophy due to aortic stenosis is associated with increased
cardiac formation of both IGF-I and ET-1.3 The increase in
cardiac IGF-I formation in both physiological hypertrophy of
athletes and pathological hypertrophy due to aortic valve disease
suggests that enhanced cardiac IGF-I formation is the primary
nonselective cardiac response to increased workload, whereas a
more selective stimulus, such as pressure overload, is required to
induce the formation of other cardiac growth factors, such as
ET-1 or Ang II. Consequently, it is conceivable that cardiac
hypertrophy in athletes performing isometric exercise might be
supported by increased formation of other growth factors in
addition to IGF-I.
TABLE 3. Univariate and Stepwise Multiple Regression
Between IGF-I Cardiac Formation or Cardiac NE Spillover and
Echocardiographic Parameters
IGF-I NE Spillover
r P r P
LVMI, g/m2 0.77* 0.001 0.54* 0.01
LVEDDI, mm/m2 0.72 0.001 0.63 0.01
Posterior wall, mm 0.46 0.01 0.23 NS
Vcf, s	1 0.43* 0.05 0.81* 0.001
Septum, mm 0.36 NS 0.16 NS
Vcf/ESS 0.29 NS 0.66 0.001
Ejection fraction, % 0.16 NS 0.23 NS
ESS, kdyne/cm2 0.02 NS 	0.21 NS
Relative wall thickness, % 0.18 NS 0.00 NS
Multiple regression 0.79 0.001 0.87 0.001
LVMI indicates left ventricular mass index; LVEDDI, left ventricular end-di-
astolic diameter index; Vcf, mean midwall velocity of circumferential fiber
shortening; and ESS, end-systolic stress.
*Independent variable at stepwise regression analysis.
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IGF-I is provided with both hypertrophying and direct inotro-
pic effects22–25 and enhances shortening velocity and cellular
compliance.26 The cellular basis for IGF-I–induced positive
inotropism is not yet completely understood, because in exper-
imental studies IGF-I has been found either to sensitize the
myofilaments to Ca2
27,28 or to increase Ca2
 availability for
myofilaments.25 These cellular activities of IGF-I are consistent
with the modifications of the echocardiographic parameters
found in the athlete group. As suggested by the univariate and
multivariate stepwise analyses of physiological hypertrophy, the
enhanced IGF-I formation seems to be mainly addressed to
increasing left ventricular mass and myocardial contractility.
Although not specifically investigated in this study, previous
investigations have shown that serum IGF-I levels were signif-
icantly increased after both endurance and strength types of
exercise and frequently remained elevated after the end of
training.29–31 Therefore, we cannot exclude that circulating
IGF-I, too, may have a role in the development of hypertrophy
in the soccer players.
Cardiac Sympathetic Activation
The second goal of our study was to investigate functional
activity of the cardiac sympathetic drive in trained athletes rather
than demonstrate the effect of acute physical exercise on either
plasma NE or the respective rate of spillover to plasma from
heart or total circulation, as previous studies did.7,8
Measurement of transmitter release by the study of [3H]NE
kinetics is a well-established technique for the assay of organ-
specific NE spillover to plasma both in physiological and
pathological conditions.32 In our investigation, the athletes
showed a significantly higher cardiac NE spillover without
significant changes in reuptake and clearance. This finding is
consistent with the marked positivity of the artery–coronary
sinus gradient of endogenous NE. Because cardiac neuronal
reuptake of NE was unaffected, the increased cardiac spillover to
plasma is proportional to the rate of cardiac sympathetic nerve
firing32 and points to an increase in cardiac sympathetic drive at
rest. Although a variety of factors may influence the rate of NE
released in the interstitial space and its passage into the plasma,
and the method of Esler32 underestimates the actual NE released
by sympathetic nerve endings,33 the clear difference in both NE
spillover and artery–coronary sinus concentration gradient be-
tween competitive athletes and sedentary control subjects indi-
cates that repetitive dynamic exercise may induce a persistent
cardiac sympathetic activation that is maintained even after
exercise has ended. A prevailing cardiac sympathetic activation
evaluated by spectral analysis was found in athletes (swimmers)
examined during the rest period of the year, ie, during a
nontraining period.34
The [3H]NE kinetics indicated that sympathetic activation in
the athlete group was selectively confined to the heart, because
plasma catecholamine concentrations and, in particular, the total
systemic NE spillover and clearance in athletes were not
significantly different from control subjects. This last finding
contrasts with the results of a previous study8 that showed a
reduction in total systemic NE spillover in 8 normal healthy
male subjects after a month of bicycle ergometer exercise, 1 hour
3 times per week. The reduction in total NE spillover to plasma
was attributed to lowering resting renal, but not cardiac, NE
spillover, which tended to increase.8 We did not investigate renal
NE spillover, but the discrepancies between the results of the
Meredith et al8 study and those of our study are probably due to
differences in the subjects investigated, duration of training, and
type of exercise.
It is worth noting the different pattern of cardiac sympathetic
activation as evaluated by [3H]NE kinetics between physiolog-
ical hypertrophy and heart failure. In both conditions there is an
increase in cardiac NE spillover, but in the latter reuptake and
clearance are notably reduced.35
Although several studies on isolated cardiomyocytes seem to
suggest a role of NE in inducing hypertrophic changes,36–38 there
is no clear evidence that NE is able to directly induce myocardial
hypertrophy in humans. In physiological hypertrophy cardiac
NE synergically acts with IGF-I in increasing inotropism be-
cause NE enhances influx of Ca2
 through slow calcium chan-
nels.39 Thus, physiological hypertrophy related to prevalently
isotonic exercise appears to be supported by the concerted action
of growth factors, ie, IGF-I and sympathetic drive.
Heart rate at rest was significantly lower in the athlete group
than in sedentary control subjects. A training-dependent de-
crease in heart rate at rest and during exercise is an adaptation
process known for a long time in isotonic athletes.40 The low
heart rate guarantees optimum ventricular filling and keeps the
loss of energy not converted to contractile force at high heart
rates from increasing disproportionately.41 Sinus bradycardia has
been attributed to an increase in vagal tone or to an alteration in
total neural input to the heart, including a decreased resting
sympathetic tone.42,43 The hypothesis that sinus bradycardia is
dependent on a reduced resting sympathetic cardiac drive con-
trasts with our results of the [3H]NE kinetics studies that
demonstrate an increased cardiac NE release and, hence, en-
hanced cardiac sympathetic nerve firing or nerve density.32
However, a sympathetic component seems to participate in the
athletes’ bradycardia at rest, because recent studies have shown
a dissociation between increased catecholamine response and
unchanged heart rate after endurance exercise training,44 sug-
gesting a decrease in sensitivity to chronotropic stimulation. This
uncoupling of inotropic and chronotropic responses might be
attributed to a selective exercise-induced downregulation in
-adrenergic receptors located in the right atrium,45 but further
investigations are required. Therefore, in the athletes a training-
dependent resetting of sympathovagal equilibrium occurs at a
higher level than in sedentary people, resulting in the apparent
paradoxical combination of simultaneous increase in vagal and
sympathetic cardiac activity.
In conclusion, the present results extend our knowledge of the
general mechanisms regulating the development of cardiac
hypertrophy and for the first time contribute to clarifying the
mechanisms responsible for the physiological hypertrophy of
endurance athletes performing isotonic exercise. Selective in-
crease in cardiac IGF-I formation and sympathetic drive are
associated with, and most likely cause, the eccentric cardiac
hypertrophy mainly due to volume-overload characteristics of
soccer players.
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